Search results for " pharmacy."

showing 10 items of 356 documents

Impact of Legislative Changes on the Availability of Medicines and Pharmacovigilance Activities

2021

Zāļu pieejamība ir vispārējas cilvēktiesības, tomēr tā joprojām saglabājas globāla problēma. Šajā pētījumā par objektu izvēlēts Latvijas lielākās kaimiņvalsts – Krievijas Federācijas (KF) – zāļu normatīvais regulējums, kurā 2010. gadā notika radikālas izmaiņas, kas noveda pie papildu administratīvā sloga un ietekmes uz zāļu pieejamību un farmakovigilances aktivitātēm. Tā kā Latvijas farmaceitiskajiem uzņēmumiem un citu Eiropas Savienības (ES) valstu zāļu ražotājiem KF tirgus ir nozīmīgs, tiem būtu noderīgi iegūt zinātnisku ieskatu zāļu reģistrāciju regulējošos procesos kas palīdzētu uzlabot to darbību. Pētījums ir nozīmīgs arī valsts iestāžu darbiniekiem, lai paredzētu sekas un plānotu norm…

Basic medical sciencesIncluding pharmacyMedicīna un farmācija
researchProduct

Innovative strategies to treat skin wounds with mangiferin: fabrication of transferosomes modified with glycols and mucin

2020

Aim: The moisturizing properties of glycerol, the penetration enhancing capability of propylene glycol and the bioadhesive properties of mucin were combined to improve the carrier capabilities of transfersomes and the efficacy of mangiferin in the treatment of skin lesions. Materials & methods: Mangiferin was incorporated in transfersomes and glycoltransfersomes, which were also modified with mucin. The physico–chemical features were assessed, along with the efficacy against oxidative stress and skin wounds in vitro and in vivo. Results: Glycoltransfersomes promoted the deposition of mangiferin in epidermis and dermis, protected fibroblasts from oxidative stress and stimulated their pr…

BioadhesiveXanthonesBiomedical EngineeringMedicine (miscellaneous)Bioengineering02 engineering and technologyDevelopmentPharmacologymedicine.disease_cause030226 pharmacology & pharmacy03 medical and health scienceschemistry.chemical_compoundGlycols0302 clinical medicineDermisIn vivoGlycerolmedicineGeneral Materials ScienceMangiferinSkinGlicolsWound Healingintegumentary systemMucinMucins021001 nanoscience & nanotechnologySkin diseasesmedicine.anatomical_structurechemistryMalalties de la pell0210 nano-technologyWound healingOxidative stress
researchProduct

Development of Polyamine‐Substituted Triphenylamine Ligands with High Affinity and Selectivity for G‐Quadruplex DNA

2019

Currently, significant efforts are devoted to designing small molecules able to bind selectively to guanine quadruplexes (G4s). These noncanonical DNA structures are implicated in various important biological processes and have been identified as potential targets for drug development. Previously, a series of triphenylamine (TPA)-based compounds, including macrocyclic polyamines, that displayed high affinity towards G4 DNA were reported. Following this initial work, herein a series of second-generation compounds, in which the central TPA has been functionalised with flexible and adaptive linear polyamines, are presented with the aim of maximising the selectivity towards G4 DNA. The acid-bas…

Biochemistry & Molecular BiologyCircular dichroismChemistry Medicinal0601 Biochemistry and Cell BiologyLigands010402 general chemistryTriphenylamineG-quadruplex01 natural sciencesBiochemistryFluorescence spectroscopyStructure-Activity Relationshipchemistry.chemical_compoundFluorescence Resonance Energy TransferPolyaminesPharmacology & PharmacyCOORDINATION CHEMISTRYPROBEMolecular BiologyScience & Technology0304 Medicinal and Biomolecular Chemistry010405 organic chemistryOrganic ChemistryDNACombinatorial chemistrySmall molecule0104 chemical sciences* G-quadruplex DNA * G4 selectivity * polyamine-based ligand *fluorescenceG-QuadruplexesFörster resonance energy transferchemistryDrug DesignFRETEQUILIBRIUM-CONSTANTSMolecular MedicineCOMPLEXESfluorescenceEMISSIONSelectivityLife Sciences & BiomedicineDNAChemBioChem
researchProduct

Effect of actively targeted copolymer coating on solid tumors eradication by gold nanorods-induced hyperthermia.

2020

Efforts in the field of anticancer therapy are increasingly focusing on the development of localized and selective treatments. Photothermal therapy (PTT) can lead to a spatially confined death of cancer cells, exploiting an increasing in temperature generated after UV-NIR irradiation of peculiar materials. Herein, a new actively targeted gold-based drug delivery system, named PHEA-LA-Fol-AuNRs/Iri, was explored for hyperthermia and chemotherapy colon cancer treatment. Gold nanorods were stabilized using a folate-derivative of α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA-LA-PEG-FA) as coating agent and then loaded with the antineoplastic drug irinotecan (Iri). The efficacy of empty and i…

BiodistributionColorectal cancerPolymersPharmaceutical Science02 engineering and technology030226 pharmacology & pharmacy03 medical and health sciencesMice0302 clinical medicineIn vivoCell Line TumorNeoplasmsmedicineGold nanorodsHyperthermiaPhotothermal therapySolid tumorMagnetic resonance imaging folic acidAnimalsHyperthermiaTissue DistributionNanotubesChemistryCancerHyperthermia InducedPhotothermal therapyPhototherapy021001 nanoscience & nanotechnologymedicine.diseaseIrinotecanDrug deliveryCancer cellCancer researchGold0210 nano-technologymedicine.drugInternational journal of pharmaceutics
researchProduct

Effect of endothelial cell heterogeneity on nanoparticle uptake.

2020

Endothelial cells exhibit distinct properties in morphology and functions in different organs that can be exploited for nanomedicine targeting. In this work, endothelial cells from different organs, i.e. brain, lung, liver, and kidney, were exposed to plain, carboxylated, and amino-modified silica. As expected, different protein coronas were formed on the different nanoparticle types and these changed when foetal bovine serum (FBS) or human serum were used. Uptake efficiencies differed strongly in the different endothelia, confirming that the cells retained some of their organ-specific differences. However, all endothelia showed higher uptake for the amino-modified silica in FBS, but, inter…

Biodistributionmedia_common.quotation_subjectReceptor expressionEndothelial cellsBristol Heart InstitutePharmaceutical ScienceUptake02 engineering and technologyADHESIONBlood–brain barrier030226 pharmacology & pharmacySERUM03 medical and health sciencesDELIVERY0302 clinical medicineBIODISTRIBUTIONmedicineHumansBovine serum albuminInternalization/dk/atira/pure/core/keywords/heart_SRImedia_commonchemistry.chemical_classificationKidneyPROTEIN-CORONAbiologyChemistryBLOOD-BRAIN-BARRIEREndothelial CellsBiological Transportrespiratory system021001 nanoscience & nanotechnologyCell biologyEndothelial stem cellSURFACE-CHARGEmedicine.anatomical_structureSIZENanomedicineTransferrinProtein coronabiology.proteinINTERNALIZATIONNanoparticlesProtein CoronaHeterogeneityMEMBRANE0210 nano-technologyEndothelial cell targetingInternational journal of pharmaceutics
researchProduct

Effects of the dual sodium-glucose linked transporter inhibitor, licogliflozinvsplacebo or empagliflozin in patients with type 2 diabetes and heart f…

2020

Aims Explore the efficacy, safety and tolerability of the dual sodium-glucose cotransporter (SGLT) 1 and 2 inhibitor, licogliflozin in patients with type-2 diabetes mellitus (T2DM) and heart failure. Methods This multicentre, parallel-group phase IIA study randomized 125 patients with T2DM and heart failure (New York Heart Association II-IV; plasma N-terminal pro b-type natriuretic peptide [NT-proBNP] >300 pg/mL) to licogliflozin (2.5 mg, 10 mg, 50 mg) taken at bedtime, empagliflozin (25 mg) or placebo (44 patients completed the study). The primary endpoint was change from baseline in NT-proBNP after 12 weeks. Secondary endpoints included change from baseline in glycated haemoglobin, fas…

Blood Glucosemedicine.medical_specialtyUrologyheart failureType 2 diabetesPlacebo030226 pharmacology & pharmacyBedtimeAnhydridesSGLT2 INHIBITORS03 medical and health sciencespharmacotherapy0302 clinical medicineDouble-Blind MethodGlucosidesDiabetes mellitusmedicineEmpagliflozinHumansHypoglycemic AgentsSorbitolPharmacology (medical)030212 general & internal medicineCOTRANSPORTER 2 INHIBITORSBenzhydryl CompoundsPharmacologyGlycated HemoglobinOUTCOMESbusiness.industrySodiumbiomarkersOriginal Articlesmedicine.diseaseEFFICACYBlood pressureGlucoseTreatment OutcomeTolerabilityDiabetes Mellitus Type 2PRESERVED EJECTION FRACTIONHeart failureSAFETYOriginal Articlebiomarkers heart failure pharmacotherapy type 2 diabetestype 2 diabetesbusinessBritish Journal of Clinical Pharmacology
researchProduct

Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Moxifloxacin Hydrochloride.

2020

Abstract In this monograph, literature data is reviewed to evaluate the feasibility of waiving in vivo bioequivalence testing and instead applying the Biopharmaceutics Classification System (BCS) based methods to the approval of immediate-release solid oral dosage forms containing moxifloxacin hydrochloride as the sole active pharmaceutical ingredient. To facilitate the feasibility decision, solubility and permeability and dissolution characteristics in the context of the BCS, therapeutic index, therapeutic use, pharmacokinetic parameters, bioequivalence/bioavailability issues, drug-excipient interactions and other relevant data were taken into consideration. Moxifloxacin is a BCS class I d…

Break pointBiowaiverMoxifloxacinPharmaceutical ScienceAdministration OralBiological AvailabilityContext (language use)02 engineering and technologyPharmacologyBioequivalenceMoxifloxacin hydrochloride030226 pharmacology & pharmacyDosage formMoxifloxacin hydrochloridePermeabilityBiopharmaceutics03 medical and health sciences0302 clinical medicineMoxifloxacinMedicinePharmacokineticsTherapeutic indexActive ingredientDosage Formsbusiness.industryBiopharmaceutics Classification System021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemBioavailabilityPharmacodynamicsSolubilityTherapeutic Equivalency0210 nano-technologybusinessmedicine.drugJournal of pharmaceutical sciences
researchProduct

Routine Use of Budesonide/Formoterol Fixed Dose Combination in Elderly Asthmatic Patients: Practical Considerations

2017

Asthma has been demonstrated to be as common in the elderly as in younger age groups. Although no specific recommendations exist to manage the disease differently in older individuals, functional features and clinical presentations may be affected by age per se, and by age-related conditions, such as comorbidities and polypharmacy. In this review article, we aimed to explore the efficacy and safety in elderly asthmatic patients of one of the most currently used inhaled treatments for asthma, that is, the fixed-dose combination of budesonide/formoterol. We attempted to address some practical questions that are relevant to the daily practice of clinicians. We focused on the efficacy and real-…

BudesonideGeriatrics & GerontologyDatabases Factuallaw.invention0302 clinical medicineRandomized controlled trialRELIEVER THERAPYlawBudesonide Formoterol Fumarate Drug CombinationDrug InteractionsPharmacology (medical)Anti-Asthmatic AgentsPharmacology & Pharmacy030212 general & internal medicineEMPHYSEMATOUS LUNGSGeriatricsPRIMARY-CAREGeriatrics and Gerontology Pharmacology (medical)Middle AgedRANDOMIZED CONTROLLED-TRIALSINGLE INHALERTreatment OutcomeDrug InteractionPractice Guidelines as TopicLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialtySettore MED/10 - Malattie Dell'Apparato RespiratorioOBSTRUCTIVE PULMONARY-DISEASE03 medical and health sciencesAdministration InhalationmedicineAnti-Asthmatic AgentHumansOLDER-PEOPLEIntensive care medicineAgedAsthmaPolypharmacyAIRWAY CLEARANCEScience & Technologybusiness.industryDRY POWDER INHALERSmedicine.diseaseAsthma030228 respiratory systemBudesonide/formoterolLUNG DEPOSITIONGeriatricsPhysical therapyIndacaterol1115 Pharmacology And Pharmaceutical SciencesFormoterolGeriatrics and GerontologybusinessDrugs & Aging
researchProduct

Impact of Undernutrition on the Pharmacokinetics and Pharmacodynamics of Anticancer Drugs: A Literature Review

2017

The etiology of undernourishment in cancer patients is multifactorial: tumor-related mechanisms (such as obstruction, metabolic abnormalities, and functionality changes) in addition to the influence of anticancer therapies, which can induce or worsen undernutrition. The evident role of undernutrition in cancer treatment outcomes suggests the need of considering nutritional status when evaluating anticancer drugs. In order to merge the available data and offer researchers and clinicians a global view of this phenomenon, the present manuscript reviews on a drug-by-drug basis the undernutrition-related pharmacokinetic and pharmacodynamic aspects of anticancer treatments. This review notes inte…

Cancer ResearchMedicine (miscellaneous)Antineoplastic AgentsPharmacologyBioinformatics030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineOtotoxicityPharmacokineticsmedicineHumansAnthracyclinesDosingVinca AlkaloidsEtoposideCardiotoxicityNutrition and Dieteticsbusiness.industryMalnutritionNeurotoxicitymedicine.diseaseCancer treatmentMalnutritionMethotrexateOncology030220 oncology & carcinogenesisFluorouracilPharmacodynamic aspectsbusinessNutrition and Cancer
researchProduct

A French prospective pilot study for identifying dihydropyrimidine dehydrogenase (DPD) deficiency in breast cancer patients (pts) receiving capecitab…

2013

e13519 Background: For fluoropyrimidines, and especially cap, Health Authorities point out that DPD deficiency confers a significant risk of major toxicity (tox). Identification of at-risk pts is thus relevant. This multicentric prospective study of the French GPCO group (Groupe de Pharmacologie Clinique Oncologique, Unicancer) evaluated the sensitivity, specificity and predictive values of DPD phenotyping and genotyping for predicting severe cap-related tox in metastatic breast cancer pts. Methods: 303 pts were included (15 institutions), 88% received cap as monotherapy, 28% were treated as first line (mean dose at 1st cycle 1957 mg/m2/d). Pre-treatment dihydrouracil (UH2) and uracil (U) …

Cancer Researchmedicine.medical_specialtymacromolecular substances030226 pharmacology & pharmacyGastroenterology[SPI.AUTO]Engineering Sciences [physics]/AutomaticCapecitabine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBreast cancerInternal medicine[ SPI.AUTO ] Engineering Sciences [physics]/AutomaticmedicineDihydropyrimidine dehydrogenaseProspective cohort studybusiness.industryDihydrouracilmedicine.diseaseMetastatic breast cancer3. Good healthSurgery[SPI.AUTO] Engineering Sciences [physics]/AutomaticOncologychemistry030220 oncology & carcinogenesisRelative riskToxicitybacteriaPublished in Journal of Clinical Oncology vol. 31 : 2013 (Suppl ;abstr e13519)businessmedicine.drug
researchProduct